Stage I: Binning Dashboard
|
|
- Jeremy Whitehead
- 5 years ago
- Views:
Transcription
1 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? Stage I: Binning Dashboard GENE/GENE PANEL: MYBPC3, MYH7, TNNT2, TNNI3, TPM1, MYL3, ACTC1, DISORDER: Familial Hypertrophic Cardiomyopathy (HCM) PRKAG2, MYL2 HGNC ID: 7551, 7577, 11949, 11947, 12010, 7584, 143, 9386, 7583 OMIM ID: Does the practice guideline or systematic review indicate that the result is actionable in one or more of the following ways? Yes No Patient Management Surveillance or Screening PENETRANCE 4. Is there at least one known pathogenic variant with at least moderate penetrance ( 40%) or moderate relative risk ( 2) in any population? SIGNIFICANCE/BURDEN OF DISEASE 5. Is this condition an important health problem? Family Management Circumstances to Avoid ( 1 of above) 3. Is the result actionable in an undiagnosed adult with the genetic condition? NEXT STEPS 6. Are Actionability (Q2-3), Penetrance (Q4), and Significance (Q5) all? (Proceed to Stage II) (Consult Actionability Working Group) Exception granted, proceed to Stage II Exception not granted, STOP 1
2 GENE/GENE PANEL: MYBPC3, MYH7, TNNT2, TNNI3, TPM1, MYL3, ACTC1, PRKAG2, MYL2 DISORDER: Familial Hypertrophic Cardiomyopathy (HCM) Topic Narrative Description of Evidence Ref 1. What is the nature of the threat to health for an individual carrying a deleterious allele? Prevalence of the genetic disorder Clinical Features HCM is a common genetic cardiovascular disease. The prevalence in the general population is estimated at 1:500, which is equivalent to at least 600,000 people affected in the United States. HCM is a primary cardiac disorder characterized by hypertrophy, usually of the left ventricle, in the absence of other loading conditions. Clinical manifestations of HCM range from asymptomatic LVH to progressive heart failure to sudden cardiac death (SCD). Progressive ventricular outflow obstruction may cause palpitation associated with arrhythmia, congestive heart failure, and sudden death. Other symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. Symptoms can be readily provoked by exercise. (1-5) (1-6) Significance/Burden Natural History HCM is a heterogeneous cardiac disease with a diverse clinical presentation and course, presenting in all age groups from infancy to the very elderly; however, left ventricular hypertrophy (LVH) often becomes apparent during adolescence or young adulthood. Although HCM was initially thought to be associated with high mortality, it is now recognized that most affected individuals will have a relatively mild course of disease and can achieve normal life expectancy without disability or the necessity for major therapeutic interventions. In some patients, HCM is associated with disease complications that may be profound with the potential to result in disease progression or premature death. An important minority of persons with HCM are at increased risk for SCD (most often occurring in adolescents or young adults) most likely related to ventricular tachycardia/ventricular fibrillation. (1;2) Approximately 5-10% of individuals with HCM progress to end-stage disease. The annual mortality rate in individuals with end-stage disease is estimated at 11%. Community-based studies suggest an annual mortality rate in the range of 1%. (1;5) HCM is the commonest structural cause of SCD in individuals less than 35 years, including competitive athletes. (3) 2. How effective are interventions for preventing the harm? Information on the effectiveness of the recommendations below was not provided unless otherwise stated. Patient Management No treatments currently exist to prevent or decrease disease development or to reverse established manifestations All patients should undergo comprehensive SCD risk stratification at initial evaluation. Patients with multiple risk factors have a substantially increased risk of sudden death sufficient to ward consideration for prophylactic therapy. In a study of 268 patients with HCM those with two or more risk factors had a lower six-year survival rate from sudden death than those with one or no risk factors (72% versus 94%). It is possible to identify most high-risk patients by noninvasive clinical markers, and only a small minority of those HCM patients who die suddenly (about 3%) are without any of the currently acknowledged risk markers. (Tier 1) SCD risk stratification is reasonable on a periodic basis (12 to 24 months) for patients with HCM who have not undergone ICD therapy. (Tier 2) It is reasonable to recommend an implantable cardioverter-defibrillator (ICD) for patients with one or more major risk factors for SCD (e.g., history of sudden death presumably due to HCM in a first-degree relative, abnormal blood pressure response during exercise, decreased leftventricular wall thickness). In an international multicenter registry of HCM patients with ICDs, patients with primary prevention ICDs placed on the basis of 1 or more of the conventional risk markers experienced appropriate ICD therapy at a rate of 4% per year. ICD therapy was effective (1) (2;3;5;7;8) 2
3 in terminating VT/VF despite the complex HCM phenotype. (Tier 2) Healthcare professionals should offer people with HCM clear and consistent information about the prevention of infective endocarditis, including the importance of maintaining good oral health, education regarding the symptoms of infective endocarditis, and the risks of invasive procedures including non-medical procedures such as body piercing or tattooing. (Tier 2) Pregnant women with HCM seeking a first trimester induced abortion should be referred to a hospital-based provider (with patient permission). (Tier 2) Patients with HCM may benefit from beta-blockers and calcium-channel blockers; however, the usefulness of these agents to alter clinical outcomes is not well established for the management of asymptomatic patients with HCM with or without obstruction. (Tier 2) (9) (10)(2;3) Surveillance Family Management Circumstances to Avoid A diagnosis of HCM is not a contraindication for pregnancy, but female patients should be carefully evaluated in regard to the risk of pregnancy. Expert maternal/fetal medical care is advised. (Tier 2) In individuals with pathogenic mutations who do not express the HCM phenotype, it is recommended to perform serial electrocardiogram, transthoracic echocardiogram (TTE), and clinical assessment at periodic intervals (every 5 years in adults), based on the patient s age and change in clinical status. One study of 235 found that at first cardiac evaluation almost onequarter of asymptomatic carriers of MYBPC3 mutations were clinically diagnosed with HCM. Risk factors for SCD were frequently present and 11% of carriers were at risk for SCD. A second study more broadly addressing 76 HCM mutation carriers with various mutations identified through DNA testing found clinical HCM in 41% of those examined. (Tier 1) 24-hour ambulatory (Holter) electrocardiographic monitoring is recommended for initial evaluation of patients with HCM to detect ventricular tachycardia (VT) and identify patients who may be candidates for ICD and upon development of palpations or lightheadedness. On routine ambulatory (Holter) 24-h ECG monitoring, non-sustained burst of ventricular tachycardia (often asymptomatic) are present in 20-30% of adult HCM patients. (Tier 1) In pregnant women with HCM, increased surveillance for fetal bradycardia is warranted. (Tier 2) First-degree relatives of an affected individual should be clinically screened for HCM. This involves physical examination by a cardiologist, an electrocardiogram, and a transthoracic echocardiogram (TTE). Screening may also include echocardiogram, CK-MM, Holter monitoring, exercise treadmill testing, and MRI. Intervals for screening vary by age (e.g. every 2-3 years until age 30), but should be individually tailored. (Tier 2) Genetic and family counseling is recommended for all patients and families with HCM. (Tier 2) Children of patients with HCM should undergo periodic TTE screening starting by age 12 years. Presence of hypertrophy frequently occurs in association with accelerated body growth during the five-year pear of the adolescent years. It is common for young affected family members <13 years old to represent silent carriers. (Tier 2) Care should be taken to avoid high dose diuretics, venodilators, and arterial vasodilators to avoid vasodilation because these may exacerbate the degree of ventricular obstruction. (Tier 2) Competitive sports should be avoided in all patients with HCM. Recreational sports in which participation is intense should also be avoided. A number of large cohort studies from the United States indicate that HCM is the most common cardiovascular cause of SCD in young athletes accounting for about one third of these events. Individuals with HCM are disqualified from sanctioned high school and college sports. (Tier 2) (2;3;11) (2;11) (2;3) 3
4 Avoid burst activities, like sprinting, as well as intense isometric exercise, such as heavy weight lifting; avoid exercise in extreme environmental conditions and maintain adequate hydration. (Tier 2) Description of sources of evidence: Tier 1: Evidence from a systematic review, or a meta-analysis or clinical practice guideline clearly based on a systematic review Tier 2: Evidence from clinical practice guidelines or broad-based expert consensus with non-systematic evidence review Tier 3: Evidence from another source with non-systematic review of evidence with primary literature cited Tier 4: Evidence from another source with non-systematic review of evidence with no citations to primary data sources Tier 5: Evidence from a non-systematically identified source GENE/GENE PANEL: MYBPC3, MYH7, TNNT2, TNNI3, TPM1, MYL3, ACTC1, PRKAG2, MYL2 DISORDER: Familial Hypertrophic Cardiomyopathy (HCM) Topic Narrative Description of Evidence Ref 3. What is the chance that this threat will materialize? Mode of Inheritance Prevalence of Genetic Mutations Autosomal dominant Information on the prevalence of HCM mutations was not identified. Penetrance OR Relative Risk (include high risk racial or ethnic subgroups) Penetrance of HCM is variable based on the underlying genotype and the age of patient at assessment. Multiple small studies of relatives of HCM probands have found that the penetrance of HCM (based on cardiac evaluation) is over 40% in at least one gene (MYBPC3). (Tier 5) One study of 653 HCM patients with an absence of SCD risk factors and no or mild symptoms (aged 10-75) found that over 10 years of follow up the cumulative sudden death risk was 5.9%. During the follow up ICDs were implanted in an additional 6% of patients based on the development of SCD risk factors. (Tier 5) N/A (12-17) (18) Expressivity HCM has variable expressivity; clinical manifestations vary from individual to individual even within the same family. 4. What is the nature of the intervention? Nature of Intervention Management of HCM includes regular invasive and non-invasive screening tests and the possible recommendation of ICD therapy, which confers appreciable risk. Reported rates of complications include approximately 25% of patients with HCM who experienced inappropriate ICD discharge; 6% to 13% who experienced lead complications (fracture, dislodgment, oversensing); 4% to 5% who developed a device-related infection; and approximately 2% to 3% who experienced bleeding or thrombosis complications. 5. Would the underlying risk or condition escape detection prior to harm in the setting of recommended care? Chance to Escape Clinical Detection General population screening recommendations are inadequate for individuals with HCM. SCD may be the first manifestation of disease. (1;4) (1) 4
5 Final Consensus Scores Gene(s) Outcome/intervention pair Severity Likelihood Effectiveness Nature of the Intervention Total Score MYBPC3 MYH7 TNNT2 TNNI3 TPM1 MYL3 ACTC1 PRKAG2 MYL2 Suddent cardiac death/icd implantation 3 2E 2B 2 9EB To see the scoring key, please go to: Date of Search: References (1) Cirino A, Ho C. GeneReview: Hypertrophic Cardiomyopathy Overview Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011 Dec 13;124(24): (3) The Cardiac Society of Australia and New Zealand, Semsarian C. Guidelines for the diagnosis and management of hypertrophic cardiomyopathy (4) Charron P. Orphanet: Familial isolated hypertrophic cardiomyopathy (5) Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS, et al ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2013 Jan 22;127(3):e283-e352. (6) McKusick V, Hamosh A. OMIM: Cardiomyopathy, Familial Hypertrophic, 1; CMH (7) National Institute for Health and Care Excellence. Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (8) Garratt CJ, Elliott P, Behr E, Camm AJ, Cowan C, Cruickshank S, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010 Aug;12(8):
6 (9) National Institute for Health and Care Excellence. Prophylaxis against infective endocarditis: Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures (10) Guiahi M, Davis A, Society of Family Planning. First-trimester abortion in women with medical conditions. Contraception 2012 Dec;86(6): (11) Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010 Jun;16(6):e (12) Calore C, De BM, Romualdi C, Lorenzon A, Angelini A, Basso C, et al. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life. J Med Genet 2015 Mar 4. (13) Terauchi Y, Kubo T, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Gender differences in the clinical features of hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Cardiol 2014 Aug 7. (14) Page SP, Kounas S, Syrris P, Christiansen M, Frank-Hansen R, Andersen PS, et al. Cardiac myosin binding protein- C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet 2012 Apr 1;5: (15) Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, Garcia-Molina E, et al. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart 2010 Dec;96(24): (16) Christiaans I, Birnie E, van Langen IM, van Spaendonck-Zwarts KY, van Tintelen JP, van den Berg MP, et al. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur Heart J 2010 Apr;31(7): (17) Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009 Nov;30(21): (18) Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014 May 1;113(9):
Stage I: Rule-Out Dashboard Secondary Findings in Adults
ACTIONABILITY Stage I: Rule-Out Dashboard GENE/GENE PANEL: MYBPC3, MYH7, TNNT2, TNNI3, TPM1, MYL3, ACTC1, DISORDER: Familial Hypertrophic Cardiomyopathy (HCM) PRKAG2, MYL2, CSRP3 HGNC ID: 7551, 7577, 11949,
More informationACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TNNT2, LMNA HGNC ID: 11949, 6636 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition?
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 11949, 6636, 2928 OMIM ID: 191045, 150330, 302045 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for
More informationStage I: Binning Dashboard
Stage I: Binning Dashboard P[ GENE/GENE PANEL: KCNQ1, KCNH2, SCN5A DISORDER: Romano-Ward Long QT Syndrome HGNC ID: 6294, 6251, 10593 OMIM ID: 192500, 613688, 603830 ACTIONABILITY PENETRANCE 1. Is there
More informationCitation for published version (APA): Christiaans, I. (2010). Hypertrophic cardiomyopathy: towards an optimal strategy
UvA-DARE (Digital Academic Repository) Hypertrophic cardiomyopathy: towards an optimal strategy Christiaans, I. Link to publication Citation for published version (APA): Christiaans, I. (2010). Hypertrophic
More informationCitation for published version (APA): Christiaans, I. (2010). Hypertrophic cardiomyopathy: towards an optimal strategy
UvA-DARE (Digital Academic Repository) Hypertrophic cardiomyopathy: towards an optimal strategy Christiaans, I. Link to publication Citation for published version (APA): Christiaans, I. (2010). Hypertrophic
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Predisposition to Inherited Hypertrophic File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_predisposition_to_inherited_hypertrophic_cardiomyopathy
More informationHereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases
Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle
More informationClinical Policy Title: Genetic testing for hereditary cardiomyopathy
Clinical Policy Title: Genetic testing for hereditary cardiomyopathy Clinical Policy Number: 02.01.21 Effective Date: October 1, 2016 Initial Review Date: August 17, 2016 Most Recent Review Date: August
More informationClinical Policy Title: Genetic testing for hereditary cardiomyopathy
Clinical Policy Title: Genetic testing for hereditary cardiomyopathy Clinical Policy Number: 02.01.24 Effective Date: October 1, 2016 Initial Review Date: August 17, 2016 Most Recent Review Date: August
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationYES NO UNKNOWN PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ATP7B DISORDER: Wilson Disease HGNC ID: 870 OMIM ID: 277900 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review,
More informationPreventing Sudden Death in Young Athletes. Outline. Scope of the Problem. Causes of SCD in Young Athletes. Sudden death in the young athlete
Preventing Sudden Death in Young Athletes Ronn E. Tanel, MD Director, Pediatric Arrhythmia Service UCSF Children s Hospital Associate Professor of Pediatrics UCSF School of Medicine Outline Sudden death
More information2011 HCM Guideline Data Supplements
Data Supplement 1. Genetics Table Study Name/Author (Citation) Aim of Study Quality of life and psychological distress quality of life and in mutation psychological carriers: a crosssectional distress
More informationWhat s new in Hypertrophic Cardiomyopathy?
What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular
More informationGenotype Positive/ Phenotype Negative: Is It a Disease?
Genotype Positive/ Phenotype Negative: Is It a Disease? Michelle Michels MD, PhD Center of Inherited Cardiovascular Diseases Erasmus MC, Rotterdam, the Netherlands No disclosures What is phenotype negative
More informationTreatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD
Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)
More informationStage I: Rule-Out Dashboard
Stage I: Rule-Out Dashboard GENE/GENE PANEL: GLA DISORDER: Fabry disease HGNC ID: 4296 OMIM ID: 301500 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic
More informationHYPERTROPHIC CARDIOMYOPATHY
HYPERTROPHIC CARDIOMYOPATHY Most often diagnosed during infancy or adolescence, hypertrophic cardiomyopathy (HCM) is the second most common form of heart muscle disease, is usually genetically transmitted,
More informationThe Management of Hypertrophic Cardiomyopathy
The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent
More informationLeft ventricular non-compaction: the New Cardiomyopathy on the Block
Left ventricular non-compaction: the New Cardiomyopathy on the Block Aamir Jeewa MB BCh, FAAP, FRCPC Section Head, Cardiomyopathy & Heart Function Program The Hospital for Sick Children Assistant Professor
More informationARVC when TO IMPLANT THE ASYMPTOMATIC PERSON
EUROPACE 2011 INHERITED ELECTRICAL CARDIAC DISORDERS ARVC when TO IMPLANT THE ASYMPTOMATIC PERSON June 26 th 2011 Robert Lemery MD CONFLICTS of INTEREST None ASYMPTOMATIC ARVC 1. ECG 2. ASYMPTOMATIC PVC
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline
More informationSteel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015
Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant
More informationClinical aspects of Arrhythmogenic Cardiomyopathies
Clinical aspects of Arrhythmogenic Cardiomyopathies INTERNATIONAL CLINICAL CARDIOVASCULAR GENETICS CONFERENCE 25 May 2018 Dr Hari Raju MBChB PhD ECES FRACP Clinical Associate Professor, Macquarie University,
More informationThe Management of HOCM: What are the Surgical Options
The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationStage I: Rule-Out Dashboard Secondary Findings in Adults
Stage I: Rule-Out Dashboard GENE/GENE PANEL: DNM2 DISORDER: DNM2-Related Intermediate Charcot-Marie-Tooth Neuropathy HGNC ID: 2974 OMIM ID: 606482 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: LMNA, EMD, FHL1 DISORDER: Emery-Dreifuss Muscular Dystrophy (AD, XL) HGNC ID: 6636, 3331, 3702 OMIM ID: 181350, 310300, 300696 ACTIONABILITY PENETRANCE 1. Is
More informationClinical Policy: Holter Monitors Reference Number: CP.MP.113
Clinical Policy: Reference Number: CP.MP.113 Effective Date: 05/18 Last Review Date: 04/18 Coding Implications Revision Log Description Ambulatory electrocardiogram (ECG) monitoring provides a view of
More information2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography,
More informationCardiac implantable electronic devices (CIEDs) in children include pacemakers and implantable cardioverter defibrillators (ICDs).
Management of Children with Cardiac Devices Guideline originally developed by Leann Miles, APRN; Lindsey Pumphrey, RN; Srikant Das, MD, and the ANGELS Team. Last reviewed by Lindsey Pumphrey, RN, Srikant
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Genetic Testing for Predisposition to Page 1 of 12 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Genetic Testing for Predisposition to Inherited Hypertrophic
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy From Genetics to ECHO Alexandra A Frogoudaki Second Cardiology Department ATTIKON University Hospital Athens University Athens, Greece EUROECHO 2010, Copenhagen, 11/12/2010
More informationHypertrophic Cardiomyopathy: beyond gradient and wall thickness
Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic
More informationApical Hypertrophic Cardiomyopathy With Hemodynamically Unstable Ventricular Arrhythmia Atypical Presentation
Cronicon OPEN ACCESS Hemant Chaturvedi* Department of Cardiology, Non-Invasive Cardiology, Eternal Heart Care Center & research Institute, Rajasthan, India Received: September 15, 2015; Published: October
More informationSudden cardiac death: Primary and secondary prevention
Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)
More informationAre there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
More informationISPUB.COM. Hypertrophic Cardiomyopathy. L Hull-Grommesh CLINICAL DESCRIPTION INCIDENCE/PREVALENCE
ISPUB.COM The Internet Journal of Advanced Nursing Practice Volume 10 Number 2 L Hull-Grommesh Citation L Hull-Grommesh.. The Internet Journal of Advanced Nursing Practice. 2008 Volume 10 Number 2. Abstract
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 6998 OMIM ID: 134610 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationProfiles in Prognosis for HCM
Japan N=3,354;20-77 y 0.17% CARDIA N=4,111; 23-35 y 0.17% Rural Minnesota N=15,137; 16-87 y 0.19% Amer Indians N=3,501;51-77 y 0.2% General Population 1:500 China N=8,080; 18-74 y 0.16% 600,000 people
More informationHYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW?
HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW? Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens LANCET 2013 ESC HCM
More informationHypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy A Presentation for the MUD meeting January, 2018 Reviewed by Bill Rooney MD VP/Medical Director 1 https://commons.wikimedia.org/wiki/file:blausen_0166_cardiomyopathy_hypertrophic.p
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Testing for Predisposition to Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy
More informationExercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart.
Exercise guidelines in athletes with isolated repolarisation abnormalities and structurally normal heart. Hanne Rasmusen Consultant cardiologist, PhD Dept. of Cardiology Bispebjerg University Hospital
More informationCardiac Conditions in Sport & Exercise. Cardiac Conditions in Sport. USA - Sudden Cardiac Death (SCD) Dr Anita Green. Sudden Cardiac Death
Cardiac Conditions in Sport & Exercise Dr Anita Green Cardiac Conditions in Sport Sudden Cardiac Death USA - Sudden Cardiac Death (SCD)
More informationClinical Genetics in Cardiomyopathies
Clinical Genetics in Cardiomyopathies Γεώργιος Κ Ευθυμιάδης Αναπληρωτής Καθηγητής Καρδιολογίας ΑΠΘ No conflict of interest Genetic terms Proband: The first individual diagnosed in a family Mutation: A
More informationSPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM
SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,
More informationCardiomyopathies. Andre Keren, MD
Cardiomyopathies Andre Keren, MD Cardiomyopathies Heart muscle disease of unknown etiology Elliott P et al. Eur Heart J 2008;29:270-276 Definition of Cardiomyopathies Elliott P et al. Eur Heart J 2008;29:270-276
More informationCardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center
Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur
More informationHypertrophic Cardiomyopathy
019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered
More informationSudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification
Sudden Death (SD) and hypertrophic cardiomyopathy (HCM) Attempt of risk stratification 84th Annual Scientific Meeting of the Aerospace Medical Association May 12-16, 2013 Sheraton Chicago Hotel & Towers,
More informationTachycardias II. Štěpán Havránek
Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia
More informationthe Young Athlete David B. Gremmels, MD Pediatric Cardiologist Children s Hospitals and Clinics of MN
Cardiovascular Risk Assessment in the Young Athlete David B. Gremmels, MD Pediatric Cardiologist Children s Heart Clinic Children s Hospitals and Clinics of MN No disclosure or financial relationships
More informationInherited Cardiomyopathies Molecular genetics and Clinical genetic testing
Inherited Cardiomyopathies Molecular genetics and Clinical genetic testing Dr Shagun Aggarwal Associate Professor, Department of Medical Genetics Nizam s Institute of Medical Sciences Adjunct Scientist,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ENG, ACVRL1, SMAD4, GDF2 DISORDER: Hereditary Hemorrhagic Telangiectasia HGNC ID: 3349, 175, 6770, 4217 OMIM ID: 187300, 600376, 175050, 615506 ACTIONABILITY
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationCardiomyopathy in Fabry s disease
Cardiomyopathy in Fabry s disease Herzinsuffizienzlunch Basel, 11.09.2018 Christiane Gruner Kardiologie, UniversitätsSpital Zürich Content Background / epidemiology Differential diagnosis Clinical presentations
More informationGenetic Screening and Double Mutation in Japanese Patients With Hypertrophic Cardiomyopathy
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGIAL ARTICLE Molecular Cardiology Genetic Screening and Double Mutation in Japanese Patients With Hypertrophic
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationCardiac Considerations and Care in Children with Neuromuscular Disorders
Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The
More informationΕμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες
Εμφύτευση απινιδωτών για πρωτογενή πρόληψη σε ασθενείς που δεν περιλαμβάνονται στις κλινικές μελέτες Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou
More informationProlonged QT Syndromes: Congenital and Acquired
Prolonged QT Syndromes: Congenital and Acquired April 30, 2014 Elizabeth S. Kaufman, MD I have no financial disclosures. MetroHealth Campus, Case Western Reserve University Prolonged QT Syndromes Congenital
More informationCME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
More informationPatient Resources: Cardiac Channelopathies
Patient Resources: Cardiac Channelopathies Overview of Cardiac Channelopathies: CPVT, Long QT Syndrome and Brugada Syndrome Heart muscle cells contract because of movement of certain molecules (called
More informationHCM GENETIC OR CLINICAL FAMILY SCREENING?
HCM GENETIC OR CLINICAL FAMILY SCREENING? Division of Inherited Cardiac Diseases Heart Center for the Young and Athletes A Dpt of Cardiology University of Athens GENETICS IN HCM DIAGNOSIS GENETIC RECOMFIRMATION
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TTR DISORDER: Hereditary transthyretin-related amyloidosis HGNC ID: 12405 OMIM ID: 105210 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationGenetic testing in Cardiomyopathies
Genetic testing in Cardiomyopathies Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University School of Medicine, New York, USA and Molecular Cardiology, IRCCS Fondazione
More informationHA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital
HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital 1 2 Sudden death an unexpected natural death within a short time period, generally 1 hour or less from the onset
More informationA novel clinical risk prediction model for sudden cardiac death in HCM: a proof of concept study
A novel clinical risk prediction model for sudden cardiac death in HCM: a proof of concept study C O Mahony,* S Rahman,** E Biagini, C Rappezzi, L Monseratt, J Gimeno, G Limongeli, A Anastasakis, W McKenna,*
More informationIs it HF secondary to rheumatic heart disease???
Is it HF secondary to rheumatic heart disease??? Is mitral regurg. Is complication of CHF??? Cardiomyopathy Definition The term cardiomyopathy is purely descriptive, meaning disease of the heart muscle
More informationPearls of the ESC/ERS Guidelines 2015 Channelopathies
Pearls of the ESC/ERS Guidelines 2015 Channelopathies Carina Blomstrom Lundqvist Dept Cardiology, Uppsala, Sweden Content 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
More informationFamilial DilatedCardiomyopathy Georgios K Efthimiadis, MD
Familial DilatedCardiomyopathy Georgios K Efthimiadis, MD Dilated Cardiomyopathy Dilated LV/RV, reduced EF, in the absence of CAD valvulopathy pericardial disease Prevalence:40/100.000 persons Natural
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationInherited Arrhythmia Syndromes
Inherited Arrhythmia Syndromes When to perform Genetic testing? Arthur AM Wilde February 4, 2017 Which pts should undergo genetic testing? SCD victims with a likely diagnosis Pts diagnosed with an inherited
More informationAnaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)
Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationLong Q. Long QT Syndrome. A Guide for
Long Q Long QT Syndrome A Guide for Introduction Long QT syndrome (LQTS) is a genetic heart disorder due to the malfunction of cardiac ion channels that results in 4,000 deaths annually in the United States
More informationClinical Cardiac Electrophysiology
Clinical Cardiac Electrophysiology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of
More informationInvasive Risk Stratification: When is it needed?
Inherited Cardiomyopathies and Channelopathies: Who is at risk for Sudden Cardiac Death? Invasive Risk Stratification: When is it needed? Hung-Fat Tse, MD, PhD Department of Medicine The University of
More informationAlcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert
University of Groningen Alcohol septal ablation for obstructive hypertrophic cardiomyopathy Steggerda, Robbert IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationI have nothing to disclose. Research support from: Cardiac Risk in The Young
I have nothing to disclose. Research support from: Cardiac Risk in The Young Pre-participation screening of Young Athletes: Current Perspective Professor Sanjay Sharma Disclosures: None SCD in Young Athletes
More informationSyncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation?
Innovations in Interventional Cardiology and Electrophysiology Thessaloniki 2014 Syncope in patients with inherited arrhythmogenic syndromes. Is it enough to justify ICD implantation? K. Letsas, MD, FESC
More informationThe Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes
The Role of Defibrillator Therapy in Genetic Arrhythmia Syndromes RHEA C. PIMENTEL, MD, FACC, FHRS UNIVERSITY OF KANSAS HOSPITAL MID AMERICA CARDIOLOGY AUGUST 19, 2012 Monogenic Arrhythmia Syndromes Mendelian
More informationHEART CONDITIONS IN SPORT
HEART CONDITIONS IN SPORT Dr. Anita Green CHD Risk Factors Smoking Hyperlipidaemia Hypertension Obesity Physical Inactivity Diabetes Risks are cumulative (multiplicative) Lifestyles predispose to RF One
More informationSABIHA GATI AND SANJAY SHARMA
9 The athlete s heart SABIHA GATI AND SANJAY SHARMA Pasieka/Science Photo Library In this article, the authors highlight the spectrum, magnitude and determinants of the athlete s heart and provide a practical
More informationNHS. Implantable cardioverter defibrillators (ICDs) for arrhythmias. National Institute for Health and Clinical Excellence. Issue date: January 2006
NHS National Institute for Health and Clinical Excellence Issue date: January 2006 Implantable cardioverter defibrillators (ICDs) for arrhythmias Understanding NICE guidance information for people with
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationFANS Paediatric Pathway for Inherited Arrhythmias*
FANS Paediatric Pathway for Inherited Arrhythmias* The pathway is based on the HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationWhat is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment. Andreas Pflaumer
What is New in CPVT? Diagnosis Genetics Arrhythmia Mechanism Treatment Andreas Pflaumer Diagnosis of CPVT Induction of different types of VES or VT by exercise or catecholamines AND exclusion of of other
More informationInvestigating the family after a sudden cardiac death. Dr Catherine Mercer Consultant Clinical Geneticist, Wessex
Investigating the family after a sudden cardiac death Dr Catherine Mercer Consultant Clinical Geneticist, Wessex Sudden adult deaths subdivided Sudden Adult Death Sudden Cardiac Death Sudden Arrhythmic
More informationPediatrics. Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment. Overview
Pediatrics Arrhythmias in Children: Bradycardia and Tachycardia Diagnosis and Treatment See online here The most common form of cardiac arrhythmia in children is sinus tachycardia which can be caused by
More informationBarry J. Maron, MD Hypertrophic Cardiomyopathy Institute Tufts Medical Center Boston, MA. Disclosures: Medtronic (Grantee) GeneDx (Consultant)
How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality Shaped by 50 Years of Clinical Research and Practice Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute
More informationGenetic Testing for Dilated Cardiomyopathy. Description
Subject: Genetic Testing for Dilated Cardiomyopathy Page: 1 of 12 Last Review Status/Date: March 2015 Genetic Testing for Dilated Cardiomyopathy Description Dilated cardiomyopathy (DCM) is characterized
More informationIndex. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AEDs. See Automated external defibrillators (AEDs) AF. See Atrial fibrillation (AF) Age as factor in SD in marathon runners, 45 Antiarrhythmic
More information